Physician profile
Nickolas Tyris
NPI 1821309154
$200,985.46
in general payments reported to CMS, 2019-2025
37 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $16K · 2021: $15K · 2022: $23K · 2023: $36K · 2024: $52K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Honoraria: $34K · Food and Beverage: $12K · Travel and Lodging: $11K · Consulting Fee: $1,800 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,812.50 |
| Honoraria | $33,500.00 |
| Food and Beverage | $11,807.50 |
| Travel and Lodging | $11,468.44 |
| Consulting Fee | $1,800.00 |
| Education | $369.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52,898.94 | 2020-2025 | Acthar |
| Amgen INC. | $35,433.31 | 2019-2025 | Krystexxa, Evenity, Prolia |
| Ani Pharmaceuticals, INC. | $33,592.61 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $30,046.30 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Enterprises LLC | $23,538.18 | 2019 | |
| Horizon Therapeutics Plc | $13,827.02 | 2021-2023 | Krystexxa, Uplizna |
| Janssen Biotech, INC. | $3,070.90 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $2,348.87 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Alexion Pharmaceuticals, INC. | $1,172.24 | 2020-2025 | Strensiq |
| Astrazeneca Pharmaceuticals Lp | $1,163.41 | 2021-2025 | Saphnelo, Evusheld |
| Ucb, INC. | $920.96 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $811.26 | 2020-2025 | |
| Genzyme Corporation | $464.12 | 2019-2025 | |
| Lilly USA, LLC | $396.95 | 2020-2024 | Taltz, Olumiant |
| Pfizer INC. | $232.24 | 2019-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Tyris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.